CRISPR FTO complexities not going anywhere in wake of Broad Institute victory, says IP chief on the CVC side
Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.